Key facts
- Altesa BioSciences’s last known valuation is $190.0M (Feb 2026).
- It has raised $114.0M across 2 recorded rounds; the latest was Later Stage VC ($75.0M) in Feb 2026.
- Notable investors include Pitango Venture Capital, Forbion, Atlantic Partners, GRA Venture Fund, Medicxi — 7 tracked in total.
- Altesa BioSciences has filed 2 Form Ds with the SEC, most recently Jul 2023 ($35.0M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Altesa BioSciences
Funding rounds
2 roundsAbout Altesa BioSciences
Developer of antiviral medicines designed for the treatment of respiratory infections and global viral threats. The company focuses on developing broad-spectrum antiviral drugs, integrating capsid inhibitors with clinical-stage research to address common respiratory viruses, enabling healthcare providers to access effective treatments that mitigate disease progression, improve patient outcomes, and reduce the burden of viral infections through targeted therapeutic interventions and regulatory-approved formulations.
- Sector
- Healthcare
- HQ
- College Park, GA, United States
- Founded
- 2020
- Employees
- 8
- Website
- altesabio.com/
- Ownership
- Privately Held (backing)
Altesa BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Altesa BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Altesa BioSciences in its N-PORT filings yet. We sweep new filings monthly.